Retroperitoneal fibrosis as a cause of obstructive uropathy. Case report
PDF (Español)
HTML (Español)

Supplementary Files

Carta de presentación (Español)


Retroperitoneal fibrosis, obstructive acute kidney injury, corticosteroids, nephrostomies, Low Back Pain, hydronephrosis.

How to Cite

Torres Serran RE, Rosselli C, Olivares Algarín CR, Vallejo Castillo C, Delgadillo Velásquez J, Quintero Barriga GC, López Correa PE. Retroperitoneal fibrosis as a cause of obstructive uropathy. Case report. Rev. Colomb. Nefrol. [Internet]. 2019 Apr. 17 [cited 2024 Jul. 25];6(2):159-65. Available from:


Retroperitoneal fibrosis is a rare, in most cases idiopathic, pathology, although it has been associated with medications, neoplasms and other connective tissue diseases. In terms of histopathology, inflammation and deposits of fibrotic tissue in the retroperitoneum are observed and, characteristically, this covers the urethra, provoking acute obstructive kidney damage, the most frequent manifestation of the disease. The definitive diagnosis is obtained solely via biopsy, and the basis of treatment is corticotherapy, although in severe cases, and where resistance to corticosteroids exists, other treatments have been used, such as immunomodulators. Occasionally, surgical interventions are necessary to manage complications. The case of a 50-year-old man who came to the Hospital emergency service due to abdominal pain is presented. Paraclinical studies showed azotemia, and diagnostic images showed left hydronephrosis with a component of interaortocaval and periaortic soft tissue. A retroperitoneal biopsy was conducted, and a diagnosis of idiopathic retroperitoneal fibrosis was made. Bilateral nephrostomies were put in place and treatment with corticosteroids was initiated
PDF (Español)
HTML (Español)


Lian L, Wang C, Tian JL. IgG4-related retroperitoneal fibrosis: a newly characterized disease. Int J Rheum Dis. 2016;19(11):1049–55.

Fujimori N, Ito T, Igarashi H, Oono T, Nakamura T, Niina Y, et al. Retroperitoneal fibrosis associated with immunoglobulin G4-related disease. World J Gastroenterol. 2013;19(1):35–41.

Vaglio A, Palmisano A, Corradi D, Salvarani C, Buzio C. Retroperitoneal Fibrosis: Evolving Concepts. Rheum Dis Clin North Am. 2007;33(4):803–17.

Palmisano A, Maritati F, Vaglio A. Chronic Periaortitis : an Update. Curr Rheumatol Rep. 2018;12:3–8.

Uibu T, Oksa P, Auvinen A, Honkanen E, Metsärinne K, Saha H, et al. Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet. 2004;363(9419):1422–6.

Goldoni M, Bonini S, Urban ML, Palmisano A, De Palma G, Galletti E, et al. Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: A case-control study. Ann Intern Med. 2014;161(3):181–8.

Graham JR, Suby HI, LeCompte PR, Sadowsky NL. Fibrotic Disorders Associated with Methysergide Therapy for Headache. N Engl J Med. 1966;274(7):359–68.

Urban ML, Palmisano A, Nicastro M, Corradi D, Buzio C, Vaglio A. Idiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach. Rev Med Interne. 2015;36(1):15–21.

Khosroshahi A, Carruthers MN, Stone JH, Shinagare S, Sainani N, Hasserjian RP, et al. Rethinking ormond’s disease: “Idiopathic” retroperitoneal fibrosis in the era of IgG4-related disease. Med (United States). 2013;92(2):82–91.

Scheel PJ, Feeley N. Retroperitoneal fibrosis: The clinical, laboratory, and radiographic presentation. Medicine (Baltimore). 2009;88(4):202–7.

Zhang W, Xue F, Wang C, Shao L. Clinical features and prognostic factors of ten patients with renal failure caused by IgG4-related retroperitoneal fibrosis. Oncotarget. 2018;9(2):2858–65.

Corradi D, Maestri R PA. Idiopathic retroperitoneal fibrosis: Clinicopathologic features and differential diagnosis. Kidney Int. 2007;72(6):742–53.

Giovanni P, Ramírez S, Barrientos MA, Alonso L, Naranjo G. Fibrosis retroperitoneal idiopática : un enigma médico. Rev Colomb Reum. 2009;16:361–73.

Vaglio A MF. Idiopathic Retroperitoneal Fibrosis. J Am Soc Nephrol. 2016;27:: 1880–1889.

Scheel PJ, Feeley N. Retroperitoneal Fibrosis. Rheum Dis Clin North Am. 2013;39(2):365–81.

Ilie CP, Pemberton RJ, Tolley DA. Idiopathic retroperitoneal fibrosis: The case for nonsurgical treatment. BJU Int. 2006;98(1):137–40.

Fry AC, Singh S, Gunda SS, Boustead GB, Hanbury DC, McNicholas TA, et al. Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: A retrospective study. Nephron - Clin Pract. 2008;108(3).

Viswaroop SB, Gopalakrishnan G. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis. Natl Med J India. 2012;25(1):26–7.

van Bommel EFH, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR. Long-Term Renal and Patient Outcome in Idiopathic Retroperitoneal Fibrosis Treated With Prednisone. Am J Kidney Dis. 2007;49(5):615–25.

Runowska M, Majewski D, Puszczewicz M. Retroperitoneal fibrosis - A report of five cases. Reumatologia. 2017;55(3):140–4.

Kermani TA, Crowson CS, Achenbach SJ, Luthra HS. Idiopathic retroperitoneal fibrosis: A retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc. 2011;86(4):297–303.

Neild GH, Rodriguez-Justo M, Wall C, Connolly JO. Hyper-IgG4 disease: Report and characterisation of a new disease. BMC Med. 2006;4:1–18.

Shiber S, Eliakim-Raz N, Yair M. Retroperitoneal fibrosis: Case series of five patients and review of the literature. Rev Bras Reumatol. 2016;56(2):101–4.

wallwork R. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine (Baltimore). 2018;97(42).

No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.




Download data is not yet available.